Additional ingredients like niacinamide, probiotics and caffeine round out this repairing formulation — all ingredients that ...

Beauty lovers know that this perfectly hued beauty product is the end-all be-all of lip balms. It's available in Black Honey ...

Motorcycle camping is the perfect blend of open-road freedom and the serenity of nature. Whether you’re a seasoned rider or a newbie planning your first trip, having the best motorcycle camping gear ...

CAMBRIDGE, Mass., June 13, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, announces new safety and ...

Beam reports breakthrough results from BEAM-101's early-stage trial for severe sickle cell disease. Read more here.

About BEAM-101 BEAM-101 is an investigational genetically modified cell therapy for the treatment of severe sickle cell disease (SCD).

New data from the BEACON trial with more patients and longer follow-up provide further demonstration of the strong clinical profile for the investigational base-editing therapy BEAM-101, as ...

Beam Therapeutics (NASDAQ:BEAM) gains FDA orphan drug status for BEAM-101 to treat sickle cell disease. Read more here.

By Robb M. Stewart Beam Therapeutics' investigational modified cell therapy for treating sickle-cell disease has been granted orphan-drug status by the Food and Drug Administration.

Beam Therapeutics’ first clinical data in the rare disease alpha-1 antitrypsin deficiency “set a bar for efficacy in the space,” according to one analyst. But the ongoing market slide poses ...

The safety profile of BEAM-101 was consistent with busulfan conditioning and autologous hematopoietic stem cell transplantation. Beam expects to present updated data from the BEACON trial in mid-2025.